Anti-PI 3 Kinase p85 alpha antibody [Ab6]
| Name | Anti-PI 3 Kinase p85 alpha antibody [Ab6] |
|---|---|
| Supplier | Abcam |
| Catalog | ab22653 |
| Prices | $394.00 |
| Sizes | 100 µg |
| Host | Mouse |
| Clonality | Monoclonal |
| Isotype | IgG1 |
| Clone | Ab6 |
| Applications | ICC/IF ICC/IF WB ICC/IF IP |
| Species Reactivities | Mouse, Rabbit, Human |
| Antigen | Recombinant full length p85 alpha protein (Human) |
| Description | Mouse Monoclonal |
| Gene | PIK3R1 |
| Conjugate | Unconjugated |
| Supplier Page | Shop |
Product images
![All lanes : Anti-PI 3 Kinase p85 alpha antibody [Ab6] (ab22653) at 1 µg/mlLane 1 : Cell lysates prepared from Jurkat cellsLane 2 : Cell lysates prepared from Raji cellsLane 3 : Cell lysates prepared from U937 cellsLane 4 : Cell lysates prepared from WR19L cellsLane 5 : Cell lysates prepared from PC12 cells](http://www.bioprodhub.com/system/product_images/ab_products/2/sub_4/11628_PI-3-Kinase-p85-alpha-Primary-antibodies-ab22653-1.jpg)
All lanes : Anti-PI 3 Kinase p85 alpha antibody [Ab6] (ab22653) at 1 µg/mlLane 1 : Cell lysates prepared from Jurkat cellsLane 2 : Cell lysates prepared from Raji cellsLane 3 : Cell lysates prepared from U937 cellsLane 4 : Cell lysates prepared from WR19L cellsLane 5 : Cell lysates prepared from PC12 cells
Product References
FBXL2- and PTPL1-mediated degradation of p110-free p85beta regulatory subunit - FBXL2- and PTPL1-mediated degradation of p110-free p85beta regulatory subunit
Kuchay S, Duan S, Schenkein E, Peschiaroli A, Saraf A, Florens L, Washburn MP, Pagano M. Nat Cell Biol. 2013 May;15(5):472-80.
Identification of mutations in distinct regions of p85 alpha in urothelial - Identification of mutations in distinct regions of p85 alpha in urothelial
Ross RL, Burns JE, Taylor CF, Mellor P, Anderson DH, Knowles MA. PLoS One. 2013 Dec 18;8(12):e84411.
Histone deacetylase 3 unconventional splicing mediates endothelial-to-mesenchymal - Histone deacetylase 3 unconventional splicing mediates endothelial-to-mesenchymal
Zeng L, Wang G, Ummarino D, Margariti A, Xu Q, Xiao Q, Wang W, Zhang Z, Yin X, Mayr M, Cockerill G, Li JY, Chien S, Hu Y, Xu Q. J Biol Chem. 2013 Nov 1;288(44):31853-66.
Comparative genomic and proteomic analysis of cytoskeletal changes in - Comparative genomic and proteomic analysis of cytoskeletal changes in
Clark R, Nosie A, Walker T, Faralli JA, Filla MS, Barrett-Wilt G, Peters DM. Mol Cell Proteomics. 2013 Jan;12(1):194-206.
Galectin-9 protein expression in endothelial cells is positively regulated by - Galectin-9 protein expression in endothelial cells is positively regulated by
Alam S, Li H, Margariti A, Martin D, Zampetaki A, Habi O, Cockerill G, Hu Y, Xu Q, Zeng L. J Biol Chem. 2011 Dec 23;286(51):44211-7.
High content screening for inhibitors of protein interactions and - High content screening for inhibitors of protein interactions and
Leuchowius KJ, Jarvius M, Wickstrom M, Rickardson L, Landegren U, Larsson R, Soderberg O, Fryknas M, Jarvius J. Mol Cell Proteomics. 2010 Jan;9(1):178-83.
Interaction of syndecan and alpha6beta4 integrin cytoplasmic domains: regulation - Interaction of syndecan and alpha6beta4 integrin cytoplasmic domains: regulation
Wang H, Leavitt L, Ramaswamy R, Rapraeger AC. J Biol Chem. 2010 Apr 30;285(18):13569-79.
Visfatin is upregulated in type-2 diabetic rats and targets renal cells. - Visfatin is upregulated in type-2 diabetic rats and targets renal cells.
Kang YS, Song HK, Lee MH, Ko GJ, Han JY, Han SY, Han KH, Kim HK, Cha DR. Kidney Int. 2010 Jul;78(2):170-81.